Fingolimod: Assay analysis of US generic capsule products reveals variation in fingolimod content beyond the recommended acceptance criteria.

Wainwright, Catherine; Fuller, Steve; Dickinson, Victoria; Greenwood, Wendy

Wainwright, Catherine; Fuller, Steve; Dickinson, Victoria; Greenwood, Wendy.

Afiliação

Wainwright C; Cycle Pharmaceuticals Ltd, The Broers Building, 21JJ Thomson Avenue, Cambridge CB3 0FA, UK. Electronic address: catherine.wainwright@cyclepharma.com.
Fuller S; Cycle Pharmaceuticals Ltd, The Broers Building, 21JJ Thomson Avenue, Cambridge CB3 0FA, UK.
Dickinson V; Cycle Pharmaceuticals Ltd, The Broers Building, 21JJ Thomson Avenue, Cambridge CB3 0FA, UK.
Greenwood W; Cycle Pharmaceuticals Ltd, The Broers Building, 21JJ Thomson Avenue, Cambridge CB3 0FA, UK.

Mult Scler Relat Disord ; 80: 105077, 2023 Dec.

Article em En | MEDLINE | ID: mdl-37864877

Assuntos

Cloridrato de Fingolimode; Esclerose Múltipla; Humanos; Cloridrato de Fingolimode/uso terapêutico; Imunossupressores/uso terapêutico; Esfingosina; Esclerose Múltipla/tratamento farmacológico; Fatores Imunológicos/uso terapêutico

Palavras-chave

Assay; Content; Fingolimod; Generic; Gilenya®; Multiple sclerosis; S1P; Sphingosine-1-phosphate receptor; Tascenso ODT®

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Cloridrato de Fingolimode / Esclerose Múltipla Limite: Humans Idioma: En Revista: Mult Scler Relat Disord Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google